| Field | Specification |
|---|---|
| Target | |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C22H19ClN4O3 |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
SC 51089 free base is a selective prostaglandin E2 EP1 receptor antagonist, with Ki values of 1.3, 11.2, 17.5, and 61.1 μM at the EP1, TP, EP3, and FP receptors, respectively. It also exhibits neuroprotective activity[1][2][3]. It is supplied as an off-white to light yellow solid (C22H19ClN4O3, MW 422.86) at 98.60% purity.
Physical & Chemical Properties
| CAS Number | 146033-03-6 |
|---|---|
| Molecular Formula | C22H19ClN4O3 |
| Molecular Weight | 422.86 g/mol |
| Purity | 98.60% |
| Appearance | Solid |
| Color | Off-white to light yellow |
| SMILES | O=C(N1C2=CC(Cl)=CC=C2OC3=CC=CC=C3C1)NNC(CCC4=CC=NC=C4)=O |
| Target | EP1, TP, EP3, FP |
| Signaling Pathway | GPCR/G Protein |
| Solubility | In Vitro: DMSO: 25 mg/mL (59.12 mM; Requires sonication; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | 4°C, sealed storage, away from moisture and light. In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Biological Activity
IC50 & Target[1]
|
EP1 1.3 μM (Ki) |
TP 11.2 μM (Ki) |
EP3 17.5 μM (Ki) |
FP 61.1 μM (Ki) |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 25 mg/mL (59.12 mM) | requires sonication; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); sealed storage, away from moisture and light; avoid repeated freeze-thaw cycles.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline |
|---|---|
| Result | ≥ 2.5 mg/mL (5.91 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.5 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL. |
Protocol 2
| Composition | 10% DMSO + 90% Corn Oil |
|---|---|
| Result | ≥ 2.5 mg/mL (5.91 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.5 mg/mL (saturation not determined). Use with caution if continuous dosing will exceed two weeks. For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 900 μL corn oil. |
Data provided by the manufacturer.
In Vitro
In neuronal cells exposed to t-BuOOH, SC 51089 free base (5 μM; 24 h) attenuates cell death induced by prostaglandin E2 (PGE2)[2].
In Vivo
In the R6/1 mouse model of HD, SC 51089 free base (40 μg/kg; infused i.p. for 28 d) improves motor coordination and balance dysfunction and reverses the long-term memory deficit[3].
| Animal Model | R6/1 mouse model of Huntington's disease (HD), from 13 to 18 weeks of age[3] |
|---|---|
| Dosage | 40 μg/kg/day |
| Administration | Infused i.p. at a rate of 0.11 μL/h during 28 days by osmotic mini-pump system |
| Result | Ameliorated motor coordination and balance dysfunction. Rescued long-term memory deficit. Improved the expression of specific synaptic markers. Reduced the number of huntingtin nuclear inclusions in the striatum and hippocampus. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
Genes Dis. 2026 Jun 15.
Podocyte mPGES-2 Determines Renal Aging and Contributes to Senile Osteoporosis. Aging Cell 2026 Jul;25(7):e70609. PMID: 42347750
Impact of Bone Morphogenetic Protein 7 and Prostaglandin receptors on osteoblast healing and organization of collagen. PLoS One 2024 May 16;19(5):e0303202. PMID: 38753641
